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a b s t r a c t
Background: Neuronal-glial tumors (ganglioglioma and dysembryoplastic neuroepithelial
tumor) are a frequent cause of focal, drug-resistant and epilepsy in children and young
adults, that is amenable for surgical treatment.
Aim of paper: Assessment of late outcome of surgical treatment and degree of seizure
control, as well as prognostic signiﬁcance of selected clinical factors.
Material and method: 52 Pediatric patients presenting with epilepsy, lesion of mesio-basal
temporal lobe and histologically veriﬁed neuronal-glial tumor treated at our facility since
2000–2011.
Results: After the mean follow-up of 2.94 years, satisfactory treatment outcome (Engel
classes I and II) was obtained in 92% of the patients (n = 48). Poor outcome (Engel class
III) was seen in 8% of patients (n = 4). New neurological deﬁcits appeared in 28% of the
patients (n = 20) but in most of them resolved over time.
Conclusions: In patients with drug-resistant epilepsy and a lesion of mesial-basal part of
temporal lobe suggestive of a glial-neuronal tumor, surgical treatment is strongly recom-
mended, aiming at excision of tumor and elimination of seizures. Histological veriﬁcation of
the lesion is a pre-requisite for optimal treatment planning. In most patients, both treatment
goals may be reached. Short duration of epilepsy prior to surgery and young age are favorable
prognostic factors. Histological diagnosis of GG, co-existence of cortical dysplasia and
location of tumor extending beyond mesial-basal temporal structures are associated with
a higher risk of postoperative complications. These may out-weight expected beneﬁts of
surgery.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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1. Introduction
Neuronal-glial tumors (ganglioglioma and dysembryoplastic
neuroepithelial tumor) are a frequent cause of focal epilepsy in
children and young adults. They account for about 40% of all
tumors located within the mesial-basal part of temporal lobe.
This anatomic area is hardly accessible to both neurophysio-
logical studies (detection of seizure activity arising here may
require special techniques, e.g. foramen ovale electrodes),
neuroimaging studies (visualization of low-grade tumors and
dysplasia-like lesions may require special MRI acquisition
techniques) and poses particular surgical problems due to
close vicinity of brainstem, cranial nerves and vessels
supplying highly eloquent brain areas. For a long time, these
lesions evaded detection leaving these patients with a vague
diagnosis of ‘‘idiopathic’’ or ‘‘cryptogenic’’ epilepsy, preclud-
ing cause-oriented and effective treatment. Only recently
advances in neuroimaging and neurophysiology enabled
detection of these lesions, their correlation with symptoms
present and their relatively safe excision. This provides a
chance for a cure of epilepsy in a considerable proportion of
patients, which is fundamental in children and young adults.
Table 1 – Engel scale assessing control of epilepsy after
surgical treatment [1].
 Class I: Seizure free or no more than a few early, non-disabling
seizures; or seizures upon drug withdrawal only
 Class II: Disabling seizures occur rarely during a period of at least
2 years; disabling seizures may have been more frequent soon
after surgery; nocturnal seizures
 Class III: Worthwhile improvement; seizure reduction for
prolonged periods but less than 2 years
 Class IV: No worthwhile improvement; some reduction, no
reduction, or worsening are possible
Table 2 – Schramm-Allashkevich classification of tem-
poral lobe tumors.
Type A (‘‘mesial’’): tumor limited to mesial-basal structures of
temporal lobe (uncus, amygdaloid nucelus, hippocampus,
parahippocampal gyrus, lingual gyrus).
Type B (‘‘temporo-lateral’’): tumor located lateral to Type A
structures but not invading inferior and middle temporal gyrus.
Type C: tumor combining features of type A and B.
Type D: tumor consistent with type C, additionally invading
temporal stem and basal part of central region of cerebral
hemisphere.
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Assessment of late outcome of surgical treatment and degree
of seizure control, as well as prognostic signiﬁcance of selected
clinical factors. Analysis encompassed a large group of
patients relatively homogenous in what relates to clinical
symptoms, location and type of lesion, diagnostic and
therapeutic algorithm and surgical technique.
3. Material and method
Inclusion criteria (lesion located in mesial-basal part of the
temporal lobe, histologically conﬁrmed neuronal-glial tumor
and at least 1 year follow-up) were fulﬁlled by 52 patients
treated at our facility since 2000–2011. This group included 31
boys and 21 girls (ratio 1.47:1), aged 1.5–18 years (mean age 10.2
years). There were 30 left-sided lesions and 22 right-sided
lesions (ratio 1.36:1). Mean follow-up was 2.94 (range 1–7
years).
Retrospective analysis of medical records took into account
history, clinical symptoms, characteristics of MRI studies,
surgical access used, results of histological studies, postoper-
ative complications and late outcome concerning epilepsy
control (assessed by the Engel scale) [1] (Table 1).
Location of tumors of the temporal lobe was assessed
according to the Schramm-Allashkevich classiﬁcation [2]
(Table 2).
Due to the predeﬁned scope of this paper, analysis
encompassed tumors of types A, C and D only.
Statistical analysis used data concerning frequency of
discrete features, mean and standard deviation, median and
quartiles, as well as ranges for continuous features. Signiﬁ-
cance of differences among distribution of data in selected
subgroups was veriﬁed using the Fisher exact test due to smallnumber of observations in groups undergoing comparison.
Discrimination analysis was used when appropriate. Signiﬁ-
cance threshold was set at p < 0.05. Results at the level of
0.06–0.09 were considered as a signiﬁcant trend. Results above
0.09 were considered as non-signiﬁcant and marked as ‘‘NS’’.
Calculations were performed using commercially available
software STATA v.10.0 (Stata Corp., College Station, TX, USA).
4. Results
4.1. Symptoms
In all cases (n = 52) the leading clinical symptom were epileptic
seizures. In 41 cases (79%) seizures persisted in spite of
seemingly adequate pharmacotherapy, thus enabling the
diagnosis of drug-resistant epilepsy. Median duration of
seizures prior to admission to our facility was 2 years (range:
1 month–13 years). The most common type of seizures were
generalized seizures (n = 29; 55%) and partial complex seizures
(n = 23; 45%).
4.2. Tumor location and surgical treatment
The most common tumor location was type A (n = 37; 69%),
while types C and D accounted for n = 11 (23%) and n = 4 (8%),
respectively. Based on MRI-determined tumor location, three
basic types of surgical approach were used. In the case of
anteriorly located type A tumors, transsylvian Yassargil
approach was used (n = 24; 46%). In posteriorly located type
A tumors, transcortical Niemeyer approach was used (n = 8;
15%). In large type A tumors and in type C and type D tumors,
Spencer anterior temporal lobectomy was used (n = 20; 39%).
In all cases, microsurgical tumor excision was performed
under neuronavigation guidance and in cases of long-lasting,
severe and drug-resistant epilepsy, intraoperative electrocor-
Table 4 – Outcome of surgical treatment of epilepsy (Engel
scale).
Class I: no seizures or auras only
Class II: up to 2 seizure days per year or nocturnal seizures only
Class III: reduction of seizure frequency by over 75%
Class IV: reduction of seizure frequency by less than 75% or no
improvement.
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secondary extra-lesional epileptogenic foci. Gross total tumor
excision was obtained in 51 cases and partial excision – in 1
case of a type D tumor (DNT, residual tumor stable over 6 years'
follow-up). Overall, within the mean follow-up period of 2.94
years, 3 patients with gross total tumor excision (no residual
tumor visible in control MRI study) presented with tumor
recurrence. In 1 case (DNT, no clinical signs, tumor recurrence
in control MRI study) the patient was reoperated 7 years
after the ﬁrst procedure, obtaining apparently complete
tumor removal. In 2 other cases (GG, no clinical signs, tumor
recurrence after 1 and 2 years, respectively), with no
tumor progression in subsequent imaging studies, patients
are observed only.
4.3. Histological studies
In our material, neuronal-glial tumors (n = 52) accounted for
74% of all tumors of mesial-basal part of temporal lobe (n = 70).
Tumor types encountered in this area are presented in Table 3.
Anatomical location of ganglioglioma (n = 48) was as follows:
type A n = 36, type C n = 10 and type D n = 2. Location of
dysembryoplastic neuroepithelial tumor (n = 4) was as follows:
type A n = 1, type C n = 1 and type D n = 2. In 16 cases (15 GG and
1 DNT), tumor co-existed with focal cortical dysplasia (type
IIIb), and in 5 – with hippocampal sclerosis (GG only) (‘‘double
pathology’’).
4.4. Seizure control
The impact of surgery on severity of epilepsy was assessed
based on the Engel scale presented in Table 4. Treatment
outcome was considered good when epilepsy was entirely or
nearly entirely eliminated (Engel classes I and II).
Within the above-mentioned mean follow-up time of 2.94
years, 87% of the patients (n = 45) are entirely seizure-free
(Engel class IA), while satisfactory treatment outcome (Engel
classes I and II) was obtained in 92% of the patients (n = 48).
Poor outcome (Engel class III) was seen in 8% of patients (n = 4).
Discontinuation of antiepileptic medication (implying cure of
epilepsy in both medical and social aspect) was possible in 40%
of the patients (n = 21).
One patient after complete excision of his tumor (GG)
underwent a repeat surgery due to persistent seizures. Despite
anatomical temporal lobectomy with hyppocampectomy
(histological study of surgical specimen revealed cortical
dysplasia), no worthwhile improvement in epilepsy control
was obtained.Table 3 – Tumors of mesial-basal area of temporal lobe in





Dysembryoplastic neuroepithelial tumor 4
Oligodendroglioma/oligodendroglioma-astrocytoma 3/1
Pilomyxoid astrocytoma 1
Ependymoma 1Looking for factors affecting anti-epileptic efﬁcacy of
surgical treatment, our population of patients was subdivided
into persons aged under 6 years (n = 16) and those aged over 6
years (n = 36). In the former group, complete cessation of
seizures (Engel class I) was obtained in all patients. In the latter
group, Engel class I result was obtained in 32/36 persons, while
the remaining 4/36 were classiﬁed as Engel class II and III. The
difference is statistically signiﬁcant ( p < 0.05), indicating that
better results may be obtained in younger patients.
Patients were also subdivided according to duration of
seizures into those with epileptic history of less than 1 year
(n = 13) and those presenting seizures for over 1 year (n = 39).
Again, in the former group, Engel class I outcome was obtained
in 12/13 persons, while in the latter – in 33/39 persons. Engel
class II/III outcome was obtained in 1/13 persons in the former
group and in 6/39 persons in the latter. The difference is
statistically signiﬁcant ( p < 0.05), indicating that shorter
duration of seizures prior to surgery is associated with a
better treatment outcome.
Worse treatment outcomes were seen in patients present-
ing with more extensive tumors (type C and type D) and in
those with coexisting cortical dysplasia, but the difference did
not reach statistical signiﬁcance.
Neither surgical approach used, scope of tumor excision
nor tumor recurrence affected late treatment outcome.
4.5. Complications
Immediately after surgery, new neurological deﬁcits appeared
in 28% of the patients (n = 20). These included: hemiparesis
(n = 18), cranial nerve III paresis (n = 4), functionally signiﬁcant
hemianopsia (n = 6), isolated aphasia (n = 3). Some patients
(n = 11) presented these disorders in various combinations.
Over the mean follow-up time of 2.94 y, out of 18 patients with
hemiparesis, in 4 cases it resolved completely and in the
remaining 14 it improved to Lovet grade 3 and 4, not
compromising the patient's overall performance. Aphasia
resolved completely in 2 cases and improved signiﬁcantly in 1.
Noteworthy is the correlation between tumor type and
postoperative complication rate. In the GG group (n = 48),
hemiparesis developed in 17 and did not resolve completely in
14, while in the DNT group (n = 4), it developed in 1 case and
resolved completely. The difference is statistically signiﬁcant
( p < 0.05).
4.6. Late outcome
Treatment outcome was assessed at least 12 months after
surgery based on the Glasgow Outcome Scale (Table 4) [3].
Satisfactory treatment outcome (GR and MD groups) was
attained by all patients analyzed. Improvement of neurologi-
cal status was seen in all patients discharged with a newly
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tion of neurological status or death were noticed.
5. Discussion
Epilepsy is one of the most frequent neurological diseases and
affects about 1% of general population [4]. In 75–80% of the
cases, seizures may be controlled by pharmacotherapy (to be
administered life-long), but in the remaining 20–25% epilepsy
proves drug-resistant [5]. One of the most frequent causes of
drug-resistant epilepsy in children are tumors within the
mesial-basal structures of temporal lobe, accounting for 40–
70% of all epilepsy-producing tumors in children [6]. Notewor-
thy is, that epilepsy is often the only clinically detectable
symptom of the tumor [7]. Most of them are low-grade gliomas;
high-grade tumors are rare at this location. Most common
histological tumor types at this location include ganglioglioma
(GG), pilocytic astrocytoma and dysembryoplastic neuroe-
pithelial tumor (DNT) [8].
Neuronal-glial tumors are listed in group 1.7 of 2007 and
2016 WHO classiﬁcation of CNS tumors (Table 5) [9,10]. Their
common feature is the presence of cells presenting tissue
markers typical both for neurons and glial cells [11,12]. Most
common representatives of this group, arising in the temporal
lobe and causing drug-resistant epilepsy are GG and DNT,
therefore for the sake of histological homogeneity, we limited
our analysis to these tumor types only. These tumors have also
several common features: epilepsy as the ﬁrst and only
symptom in over 95% of the patients, young age at presenta-
tion and very slow clinical progression [13].
Computed tomography may detect about 50% of lesions in
mesial-basal area of the temporal lobe. Advent of modern
neuroimaging techniques, mainly high deﬁnition magnetic
resonance, contributed to a signiﬁcant reduction of number of
cases previously described as ‘‘non-lesional’’, ‘‘cryptogenic’’ or
‘‘idiopathic’’. Modern MRI devices may detect structural
lesions in nearly 100% of patients. Radiological image is
similar in most cases. With T1 relaxation time, most tumors
are hypointense and with T2 relaxation time–hyperintense. In
FLAIR images nearly all are hyperintense [14]. They enhance
heterogeneously with contrast media, rarely present peri- or
intratumoral cysts and calciﬁcations are less common than
with other locations. In the diagnosis of medial-basal temporal
tumors, functional MRI is rarely performed due to lack of
standardized techniques enabling location of memory and
speech functions, particularly in young patients. Furthermore,Table 5 – Glasgow Outcome Scale.
GR (good result) – good overall condition, no deﬁcits or mild
neurological or cognitive deﬁcit not affecting normal functioning
(professionally active).
MD (moderate disability) – good overall condition, moderate
neurological and cognitive deﬁcit, patient independent in
everyday activities.
SD (severe disability) – severe deﬁcit, patient dependent on others
in everyday activities.
VS (vegetative state).
D (death).MR study in non-cooperative children requires general
anesthesia, so fMRI in small children is impossible [15].
Ganglioglioma accounts for about 1.3% of all CNS tumors in
children and is usually circumscribed but may invade pia-
arachnoid. This may cause problems with total excision,
putting at risk adjacent vessels and other structures and
resulting in signiﬁcantly higher complication rate, as shown in
our material. The tumor is composed of a mixed population of
neurons and malignant glial cells. Glial component usually is
consistent with pilocytic astrocytoma, rarely with other
astroglial tumors. Tumor cells express both neuronal markers
(synaptophysin and neuroﬁlament epitopes) and glial markers
(glial ﬁbrillary acidic protein). Degree of malignancy depends
on severity of anaplasia within the glial component [16–18].
Dysembryoplastic neuroepithelial tumor (DNT) accounts
for about 13.5% of all CNS tumors in children. It may take 3
histological forms: simple (tumor tissue is composed of typical
neuronal-glial cells), complex (tumor tissue is composed by
glial nodules, glial-neuronal cells, foci of cortical dysplasia and
disorganized cytoarchitecture) and non-speciﬁc (taking an
atypical morphological appearance). Tumor may be sur-
rounded by areas of disordered layered architecture consistent
with focal dysplasia IIIb and neuronal heterotopias [12,19,20].
In our material, the incidence GG and DNT in mesial-basal
area of temporal lobe is completely different to that reported
for the entire CNS. This ﬁnding is noteworthy, indicating a
possible local preference of speciﬁc types, also found else-
where in the brain and concerning other tumor types [21].
Glial neuronal tumors usually take a benign clinical course
and for several years may be stable, both in terms of severity of
symptoms and radiological appearance. This is also conﬁrmed
by our ﬁndings. Malignant transformation, although described
in the literature, is rare [22].
Epilepsy caused by a lesion within the mesial-basal part of
temporal lobe usually has a typical symptom proﬁle, exacer-
bates over time and in most cases proves resistant to
pharmacotherapy. Particularly in young children, uncontrol-
lable seizures result in progressive deterioration of cognitive
functions and psychomotor retardation. Noteworthy is,
that even clinically asymptomatic bioelectric seizures may
result in severe behavioral disorders and deterioration of
cognitive functions. Therefore, surgical treatment should
always be considered, according to the principle ‘‘the sooner
the better’’. In our material, better outcomes were obtained in
younger children and in those with shorter duration of their
disease [23].
The mechanism of epileptogenesis in CNS tumors is not
fully understood. At macroscopic level, there is direct
compression and irritation of brain cortex and local alteration
of brain perfusion. At the cellular level there is neuronal loss,
glia proliferation, altered cell physiology, altered level and
composition of neurotransmitters, calcium, glutamate and
free radicals, affecting both neurons and glia. Altered
composition of extracellular ﬂuid and inter-cellular junctions
may also play a role. As a result, neurons adjacent to the tumor
show disturbed mechanisms of control of excitation and
inhibition, resulting in hypersensibility of neurons to external
stimuli (both electric and chemical) and synchronous dis-
charges of large groups of cells. Secondary epileptogenic foci
developing over time may be functional (at ﬁrst) or structural
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secondary foci may disappear spontaneously. An epilepto-
genic focus is not equivalent with the tumor, thus conﬁrming
the thesis about multifactorial etiology of epilepsy. This has
been also conﬁrmed by our ﬁndings, where excision of tumor
does not necessarily eliminate the epilepsy [24–26].
A separate problem associated with prolonged pharmaco-
therapy are side effects of anti-epileptic drugs (cognitive
disorders, teratogenic effect on the fetus, hepatotoxicity,
gingival hypertrophy, etc.), not to mention economic burden
of life-long drug dependency. Thus the importance of a
potentially curative procedure, enabling discontinuation of
pharmacotherapy in a signiﬁcant proportion of patients [27–29].
In terms of surgical strategy, tumors of mesial-basal
temporal lobe pose essentially two interdependent clinical
problems: tumor and epilepsy. Management must be compre-
hensive and aiming at elimination of both conditions. As in
other ﬁelds of neurosurgery, the main goal of surgery is as
complete as possible tumor excision without causing severe
and permanent neurological deﬁcits, that might signiﬁcantly
compromise the patients' quality of life. In the case of tumors
of mesial-basal part of temporal lobe, surgical accessibility,
low-grade histology, relatively well deﬁned margins and
modern surgical technique, enable complete excision of both
lesion and co-existing epileptogenic focus, providing both
oncological and neurological cure. However, even small
residual tumor or epileptogenic focus may increase the risk
recurrence and persistence of epilepsy. Seizures may recur
even several years after an apparently radical surgery. In our
material, treatment outcome in terms of antiepileptic efﬁcacy,
was stable over 2 years' follow-up [30–32].
There are three basic strategies: lesionectomy (excision of
lesion within it's anatomical boundaries), lesionectomy with
focectomy (excision of lesion with adjacent epileptogenic
focus) and lobectomy (excision of part of entire temporal lobe
containing structural and functional lesions) [32,33]. In our
facility, surgical strategy depends on tumor location, size
and discernible epileptogenic focus. The following approaches
are used:
- Anterior-mesial temporal excision (m. Spencer), consisting
in excision of temporal pole (3–3.5 cm) and mesial structures
but with sparing of the superior temporal gyrus (a less
extensive procedure compared to classic lobectomy reduces
the risk of postoperative speech and visual ﬁeld deﬁcits) [33].
- Selective anterior amygdalo-hippocampectomy (m. Yassar-
gil) used in lesions of anterior part of hippocampus,
approached through the lateral (Sylvian) ﬁssure [35,36].
- Selective posterior amygdalo-hippocampectomy (m. Nie-
meyer) used in lesions of posterior part of hippocampus,
approached through the middle temporal gyrus [34].
Subtemporal approach upon retraction of temporal lobe is
rarely used nowadays, due to frequent complications caused
by disruption of the vein of Labbe and contusion of undersur-
face of temporal lobe [35].
Surgery is always a serious and irreversible intervention
into vital brain areas. Mortality (early and delayed) associated
with surgical treatment of tumors of mesial-basal area of
temporal lobe is estimated at 0–2%. Perioperative death iscaused usually by infection, hydrocephalus, hematoma or
vasospasm and brain ischemia, while delayed death is caused
usually by status epilepticus [36].
Morbidity rate is estimated at about 20% and has not
decreased substantially within the past 30 years [37]. Compli-
cations may be subdivided into cognitive and neurological.
The most common cognitive disorder associate with temporal
lobe surgery is memory deﬁcit [38]. It rarly develops in children
but is far more common in adults with several years' long
epileptic history. Neurological complications include motor
aphasia (caused by damage to Broca's area and to the
uncinated fascicle), visual ﬁeld deﬁcit (caused by damage to
Meyer's loop, optic tract or choroidal artery), hemiparesis
(damage to vessels supplying the central region) or diplopia
(damage to nerve III and IV). The risk thereof may be reduced
by limiting excision of the superior temporal gyrus to 3 cm and
of middle temporal gyrus to 4.5 cm from the pole, by sub-
arachnoid excision of the hippocampus and preservation
of choroidal artery and nerves. The key issue is expertise
and anatomical orientation on the part of operating surgeon
[36–38].
In our material, fewer complications were seen in younger
patients and in those harboring a DNT. It appears that growth
pattern of GG with invasion of pia-arachnoid (as opposed to
DNT, which is usually far better circumscribed) favors intraop-
erative damage to adjacent structures. The role of age is less
evident in this context. This issue requires further study but a
possible explanation is that functional disturbances are much
more difﬁcult to detect in small and uncooperative children. On
the other hand, young people much better restore lost
neurological function. Our results conﬁrm these ﬁndings and
further support the claim to operate these patients as early as
possible.
Arguments promoting surgery in younger patients include:
generally worse outcome of anti-epileptic pharmacotherapy
than in adults, enhanced risk of developing side effects of anti-
epileptic drugs, economic burden of treatment, social stigma-
tization, deterioration of quality of life, arrest of psychomotor
development, intellectual collapse and risk of death during an
uncontrollable status epilepticus. Gravity of these factors is
further enhanced by a far longer expected survival time in
children than in adults [39–41].
In the case of GG and DNT, the natural course of the disease
is known and surgery provides at least an 80% chance of
elimination of seizures, enabling normal psychomotor devel-
opment and ensuring an acceptable quality of life. Qualifying a
patient for surgical treatment requires a careful consideration
of expected beneﬁts and possible risk. In the setting of
temporal epilepsy, superiority of surgical over conservative
treatment has been demonstrated by prospective randomized
trial. In 2003, American Academy of Neurology recommended
surgical treatment as the ﬁrst-choice option in drug-resistant
epilepsy [42,43].
6. Conclusions
1. In patients with drug-resistant epilepsy and a lesion of
mesial-basal part of temporal lobe suggestive of a glial-
neuronal tumor, surgical treatment is recommended,
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 2 – 8 7aiming at excision of tumor and elimination of seizures.
Histological veriﬁcation of the lesion is a pre-requisite for
optimal treatment planning.
2. In most patients, both treatment goals may be reached.
3. Short duration of epilepsy prior to surgery and young age
are favorable prognostic factors.
4. Histological diagnosis of GG, co-existence of cortical
dysplasia and location of tumor extending beyond mesi-
al-basal temporal structures are associated with a higher
risk of postoperative complications. These may out-weight
expected beneﬁts of surgery.
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